Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 3Sarcoma 2Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Sarcoma 1Lymphoma 1Gliosarcoma 1Glioblastoma 1Carcinoma 1

Interventions

Temozolomide 62Cyclophosphamide 60Radiotherapy 48Doxorubicin 36Filgrastim 26Radiation 24Irinotecan 24fludarabine 23Gemcitabine 23Magnetic Resonance Spectroscopy 21Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Tetanus Toxoid × Sarcoma × Clear all
NCT00639639 2023-03-13

ATTAC

Duke University

Phase 1 Completed
42 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01644968 2022-05-17

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Providence Health & Services

Phase 1 Completed
30 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡